Studies Linking Lacosamide to Cardiac Risks
Lacosamide, an antiepileptic drug (Vimpat), has been associated with cardiac conduction abnormalities in clinical studies and post-marketing data. A 2010 phase 3 trial (SP756) reported PR interval prolongation in 4.5% of patients on 400 mg/day versus 1.1% on placebo, with second-degree atrioventricular (AV) block in some cases.[1] Pooled data from three randomized trials showed dose-dependent PR prolongation, peaking at 9.6 ms with 600 mg/day.[2]
Key Cardiac Events in Trials
In pivotal trials (SP667, SP754, SP755), serious cardiac adverse events occurred in 0.4% of lacosamide-treated patients, including AV block and atrial fibrillation or flutter. A long-term open-label extension study (SP772) followed 1,154 patients for up to 8 years, noting 0.8% incidence of second- or third-degree AV block.[3] These risks were higher in patients with preexisting conduction issues.
FDA Warnings and Labeling Updates
The FDA label warns of PR prolongation, AV block, and atrial tachyarrhythmias, recommending ECG monitoring in patients with cardiac disease or on drugs affecting conduction (e.g., beta-blockers).[4] Post-approval reports via FAERS database (up to 2023) include over 500 cardiac-related events, though causality is not always confirmed.[5]
Use in Patients with Heart Disease
No large dedicated studies exist for lacosamide in heart disease populations, but subgroup analyses show elevated risks: a 2018 review found 2-3x higher AV block rates in those with baseline cardiac conditions.[6] Guidelines (AAN/AES) advise caution or avoidance in severe conduction disorders, with monitoring for symptoms like syncope.[7]
Ongoing Research and Real-World Data
Recent cohort studies, like a 2022 Danish registry analysis (n=6,000+), reported 1.5% cardiac arrhythmia risk with lacosamide versus other anti-seizure meds, particularly in elderly patients.[8] A 2023 meta-analysis of 10 trials confirmed dose-related QT prolongation (minimal) and PR effects but no increased sudden death risk.[9]
[1]: Biton et al., Epilepsia 2010
[2]: Vadlamudi et al., Epilepsia 2010
[3]: Kaufman et al., Epilepsia 2014
[4]: FDA Vimpat Label
[5]: FAERS Public Dashboard
[6]: Maher et al., CNS Drugs 2018
[7]: Glauser et al., Epilepsy Curr 2013
[8]: Christiansen et al., Epilepsia 2022
[9]: Li et al., Front Neurol 2023